**PATENT ASSIGNMENT**

Electronic Version v1.1  
Stylesheet Version v1.1

<table>
<thead>
<tr>
<th>SUBMISSION TYPE:</th>
<th>NEW ASSIGNMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>NATURE OF CONVEYANCE:</td>
<td>ASSIGNMENT</td>
</tr>
</tbody>
</table>

**CONVEYING PARTY DATA**

<table>
<thead>
<tr>
<th>Name</th>
<th>Execution Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crimagua Limited</td>
<td>09/14/2009</td>
</tr>
</tbody>
</table>

**RECEIVING PARTY DATA**

<table>
<thead>
<tr>
<th>Name:</th>
<th>Janssen Alzheimer Immunotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Street Address:</td>
<td>Little Island Industrial Estate</td>
</tr>
<tr>
<td>City:</td>
<td>Little Island, County Cork</td>
</tr>
<tr>
<td>State/Country:</td>
<td>IRELAND</td>
</tr>
</tbody>
</table>

**PROPERTY NUMBERS Total: 1**

<table>
<thead>
<tr>
<th>Property Type</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patent Number:</td>
<td>6787140</td>
</tr>
</tbody>
</table>

**CORRESPONDENCE DATA**

Fax Number: (415)576-0300  
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.  
Phone: 650-326-2400  
Email: mrcaitiis@townsend.com  
Correspondent Name: Rosemarie L. Celli  
Address Line 1: TOWNSEND and TOWNSEND and CREW LLP  
Address Line 2: Two Embarcadero Center, 8th Floor  
Address Line 4: San Francisco, CALIFORNIA 94111-3834

**ATTORNEY DOCKET NUMBER:** 15270J-004726US

**NAME OF SUBMITTER:** Rosemarie L. Celli

Total Attachments: 8
source=J_004720US_C_to_JAI#page1.tif  
source=J_004720US_C_to_JAI#page2.tif  
source=J_004720US_C_to_JAI#page3.tif  
source=J_004720US_C_to_JAI#page4.tif  
source=J_004720US_C_to_JAI#page5.tif
ASSIGNMENT

THIS ASSIGNMENT, by CRIMAGUA LIMITED, a private limited company incorporated under the laws of Ireland and having its registered office at Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland and successor in interest to Elan Pharma International Limited (hereinafter referred to as "the Assignor"), witnesseth:

WHEREAS, the Assignor is the owner of the entire right, title and interest of the invention set forth as follows:

Title of Invention: PREVENTION AND TREATMENT OF AMYLOIDGENIC DISEASE

US Application No.: 09/201,430

Filing Date: November 30, 1998

US Patent No.: 6,787,523

Grant Date: September 7, 2004

WHEREAS, JANSSEN ALZHEIMER IMMUNOTHERAPY (formerly known as Juno Neurosciences), a private unlimited company incorporated under the laws of Ireland, and having its registered office at Little Island Industrial Estate, Little Island, County Cork, Republic of Ireland (hereinafter referred to as "the Assignee"), pursuant to an Asset Purchase Agreement dated as of July 2, 2009 (hereinafter referred to as “the Janssen APA”), among Assignor, Assignee, Janssen Pharmaceutical, Elan Corporation, plc, Elan Pharmaceuticals, Inc. and Athena Neurosciences, Inc., has acquired the Assignor's right, title, and interest in and to said invention and the right, title and interest in and to any applications, including provisional applications, for Letters Patent of the United States or other countries claiming priority to said applications, and in and to any Letters Patent or Patents of any country, to be obtained therefor and thereon;

NOW, THEREFORE, pursuant to the Janssen APA, for good and sufficient consideration, the receipt of which is hereby acknowledged, effective as of the Closing Date (as such term is defined in the Janssen APA), Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over unto the Assignee, and Assignee's successors, legal representatives, and assigns, all of the Assignor's right, title, and interest in and to the above-mentioned invention, the right to file applications on said invention and the right, title and interest in and to any applications, including provisional applications, for Letters Patent of the United States or other countries claiming priority to said applications, and any and all Letters Patent or Patents of the United States of America and all foreign countries that have been or may be granted therefor and thereon, and in and to any and all applications claiming priority to said applications, divisions, renewals, substitutions, conversions, continuations, and continuations-in-part of said applications, and reissues, prolongations and extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the
term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by the Assignor had its sale and assignment not been made;

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, their successors, legal representatives, and assigns, that the Assignor will, whenever counsel of the Assignee, or the counsel of their successors, legal representatives, and assigns, shall advise that any proceeding in connection with said invention or said applications for Letters Patent or Patents, or any proceeding in connection with Letters Patent or Patents for said inventions in any country, including interference proceedings, is lawful and desirable, or that any application claiming priority to said application, division, continuation, continuation-in-part, substitution or conversion of any applications for Letters Patent or Patents, or any reissue, prolongation or extension of any Letters Patent or Patents to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said inventions, without charge to the Assignor, its successors, legal representatives, and assigns;

AND the Assignor hereby requests the Commissioner of Patents to issue any and all said Letters Patent or Patents of the United States to the Assignee as the Assignee of said invention and the Letters Patent or Patents issued and to be issued thereon for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

IN TESTIMONY WHEREOF, Assignor has signed its name on the date indicated.

CRIMAGUA LIMITED

Date: September 14, 2009

By: ____________________________

Name: __________________________

Title: __________________________

Subscribed to by __________________________
with whose identity I have first satisfied myself
this 14th day of September, 2009.

Andrew F. Smyth, Notary Public
21 Clare Street, Dublin 2
Commissioner
CLOSING CONFIRMATION

This closing confirmation is dated as of September 17, 2009. Reference is made to (a) that certain Asset Purchase Agreement dated as of July 2, 2009 (hereinafter referred to as “the Crimagua APA”), among Elan Pharma International Limited, Crimagua Limited, Elan Corporation, plc, Elan Pharmaceuticals, Inc., Neuralab Limited and Athena Neurosciences, Inc. and (b) that certain Asset Purchase Agreement dated as of July 2, 2009 (hereinafter referred to as “the Janssen APA”), among Crimagua Limited, Janssen Pharmaceutical, Janssen Alzheimer Immunotherapy (formerly known as Juno Neurosciences), Elan Corporation, plc, Elan Pharmaceuticals, Inc. and Athena Neurosciences, Inc.

The undersigned, being all the parties to the Crimagua APA and Janssen APA, hereby acknowledge and agree that the Closing Date (as such term is defined in the Crimagua APA) and the Closing Date (as such term is defined in the Janssen APA) occurred on September 17, 2009 and that all sales, assignments, transfers and set overs of intellectual property under the Crimagua APA or Janssen APA contingent on the effectiveness of such dates are now effective in accordance with the terms of the Crimagua APA or Janssen APA, as applicable.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
IN WITNESS WHEREOF, the parties have duly executed this closing confirmation as of the date first written above.

ELAN CORPORATION, PLC,

by

Name: WILLIAM DANIEL
Title: EVP & COMPANY SECRETARY

ELAN PHARMA INTERNATIONAL LIMITED,

by

Name: WILLIAM DANIEL
Title: DIRECTOR

ELAN PHARMACEUTICALS, INC.,

by

Name:
Title:

NEURALAB LIMITED,

by

Name:
Title:

ATHENA NEUROSCIENCES, INC.,

by

Name:
Title:

CRIMAGUA LIMITED,

by

Name: WILLIAM DANIEL
Title: DIRECTOR
IN WITNESS WHEREOF, the parties have duly executed this closing confirmation as of the date first written above.

ELAN CORPORATION, PLC,

by

_________________________

Name:  
Title:  

ELAN PHARMA INTERNATIONAL LIMITED,

by

_________________________

Name:  
Title:  

ELAN PHARMACEUTICALS, INC.,

by

_________________________

[Signature]
Name:  John L. Donahue
Title:  Assistant Secretary

NEURALAB LIMITED,

by

_________________________

Name:  
Title:  

ATHENA NEUROSCIENCES, INC.,

by

_________________________

[Signature]
Name:  John L. Donahue
Title:  Assistant Secretary

CRIMAGUA LIMITED,

by

_________________________

Name:  
Title:  

Signature Page to Closing Confirmation
IN WITNESS WHEREOF, the parties have duly executed this closing confirmation as of the date first written above.

ELAN CORPORATION, PLC,

by

Name:
Title:

ELAN PHARMA INTERNATIONAL LIMITED,

by

Name:
Title:

ELAN PHARMACEUTICALS, INC.,

by

Name:
Title:

NEURALAB LIMITED,

by

Name: Kevin P. Kelly
Title: President

ATHENA NEUROSCIENCES, INC.,

by

Name:
Title:

CRIMAGUA LIMITED,

by

Name:
Title:
JANSSEN PHARMACEUTICAL,
by

Name: Ivan Cartagena
Title: Director

JANSSEN ALZHEIMER
IMMUNOTHERAPY,
by

Name:
Title:
JANSSEN PHARMACEUTICAL,

by

Name: 
Title: 

JANSSEN ALZHEIMER IMMUNOTHERAPY,

by

Name: [Signature]
Title: [Signature]

DIRECTOR

Signature Page to Closing Confirmation